Cerevel Therapeutics Holdings, Inc. (CERE)

42,19 -0,11 (-0,26%) Börsenschluss: 04:00PM EDT

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
https://www.cerevel.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 355

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. N. Anthony Coles Jr., M.P.H.	Executive Chairman	729,77k	13,53M	1960
Mr. Ronald C. Renaud Jr., M.B.A.	President, CEO & Director	1,03M	N/A	1969
Dr. Susan Altschuller M.B.A., Ph.D.	Chief Financial Officer	633,06k	N/A	1982
Mr. Mark Bodenrader	Senior VP of Finance & Chief Accounting Officer	508,39k	N/A	1973
Dr. John J. Renger Ph.D.	Chief Scientific Officer	689,25k	N/A	1969
Dr. Ramiro Sanchez M.D.	Chief Medical Officer	711,57k	1M	1961
Mr. Paul D. Burgess J.D.	Chief Business Development & Strategic Operations Officer	545,72k	N/A	1974
Mr. Matthew Calistri	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Scott M. Akamine J.D.	Chief Legal Officer & Corporate Secretary	444,74k	N/A	1985
Mr. Kenneth A. DiPietro	Chief Human Resources Officer	N/A	N/A	1959

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cerevel Therapeutics Holdings, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 8, Vorstand: 7, Shareholderrechte: 5, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.